Clinical Trial Phases Explained: What Happens in Phase 1, 2, 3, and 4
Clinical trials progress through four main phases before a drug or treatment can reach the market, and a fifth phase of monitoring afterward. Phase 1 tests basic safety in a small group. Phase 2 checks whether the treatment works and watches for side effects. Phase 3 confirms results in a large, diverse population. Phase 4 tracks the product once it’s available to the public.
Each phase answers a different question, and a drug or supplement ingredient must pass one phase before moving to the next. Understanding what each phase actually proves helps you judge how strong a piece of “clinical evidence” really is when you see it cited in a product description or news article.
Phase 1: Is It Safe? Phase 1 studies typically enroll 20 to 100 people, according to the U.S. Food and Drug Administration (FDA). Most participants are healthy volunteers, though people with the target condition may be included when the drug is intended for a serious illness such as cancer. Researchers start with a low dose and slowly increase it while closely watching for adverse events. The goal is to find out how the body processes the substance and what dose people can tolerate. Phase 1 studies usually last several months, and the FDA reports that roughly 70% of drugs move on to Phase 2.
Phase 2: Does It Work, and What Are the Side Effects? Phase 2 studies expand to up to several hundred participants who actually have the condition the treatment targets. This phase starts to look at whether the treatment produces a benefit, while continuing to collect safety data. Phase 2 studies aren’t large enough on their own to prove a treatment works, but they’re used to refine the dose, the endpoints (the specific outcomes researchers measure), and the study design for Phase 3. The FDA notes that about 33% of drugs advance past this stage.
Phase 3: Does It Work in a Large, Diverse Group? Phase 3 trials, sometimes called pivotal studies, enroll 300 to 3,000 participants and often run for one to four years. These trials are frequently randomized, double-blind, and placebo-controlled, meaning participants are randomly assigned to the treatment or a control group, and neither participants nor researchers know who received which until the study ends. This design limits bias and produces the strongest evidence in the drug development process. Because Phase 3 trials are larger and longer, they’re also more likely to catch rare or long-term side effects that smaller studies missed. Roughly 25% to 30% of drugs that reach Phase 3 go on to the next step, per FDA data.
Phase 4: What Happens After Approval? Phase 4 trials happen after the FDA has approved a drug for marketing. These studies can involve several thousand participants and fall under what’s known as post-market surveillance. Because far more people use a drug once it’s approved than were ever enrolled in trials, Phase 4 monitoring can surface rare side effects, long-term risks, or interactions that smaller, shorter trials couldn’t detect.
Clinical Trial Phase Comparison
Here’s how the phases compare on purpose, typical participant count, duration, advancement rate, and what each one actually proves.
- Phase 0 — Purpose: microdosing/pharmacokinetics. Participants: fewer than 15. Duration: days to weeks. Advancement rate: not a formal go/no-go phase. What it proves: whether the substance behaves as expected in the body at a very low dose.
- Phase 1 — Purpose: safety and dosage. Participants: 20 to 100. Duration: several months. Advancement rate: approximately 70%. What it proves: basic safety and a tolerable dose range.
- Phase 2 — Purpose: efficacy and side effects. Participants: up to several hundred. Duration: several months to 2 years. Advancement rate: approximately 33%. What it proves: an early signal that the treatment may work, plus more safety data.
- Phase 3 — Purpose: efficacy confirmation and adverse reaction monitoring. Participants: 300 to 3,000. Duration: 1 to 4 years. Advancement rate: approximately 25-30%. What it proves: whether the treatment offers a real benefit in a large, diverse population.
- Phase 4 — Purpose: post-market safety and efficacy. Participants: several thousand. Duration: ongoing after approval. Advancement rate: not applicable, already approved. What it proves: real-world safety and long-term effects across a broad population.
Note: participant ranges and advancement rates reflect FDA data for drug trials. Timelines vary by therapeutic area, and supplement ingredient research often uses smaller studies that don’t always follow this exact framework.
What Is a Phase 0 Clinical Trial?
A Phase 0 trial, sometimes called an “early Phase 1” study, is a very small, short study that comes before standard Phase 1 testing. It typically enrolls fewer than 15 people and uses a very low dose to check whether a substance behaves in the human body the way lab and animal research predicted.
Phase 0 studies aren’t a required step in drug development, and not every treatment goes through one. Researchers use them mainly to catch early problems before committing to a full-scale Phase 1 trial. Because the doses are so low and the sample size so small, a Phase 0 study can’t tell you whether a treatment is safe at a therapeutic dose or whether it actually works. If you see a supplement ingredient described only by “Phase 0” or “preliminary” research, treat that as an early signal, not proof of a health benefit.
How Long Does Each Clinical Trial Phase Take?
Clinical trial phases can take anywhere from a few months to several years, with Phase 1 usually the shortest and Phase 3 usually the longest. In total, the FDA drug review process notes that clinical research and regulatory review together can span many years from the first human dose to final approval.
Phase 1 generally takes several months. Phase 2 can run from several months up to two years. Phase 3, the largest and most rigorous phase, typically takes one to four years because researchers need enough time and enough participants to detect meaningful differences in outcomes and to catch less common side effects. After Phase 3 finishes, the sponsor still has to prepare and submit an application to the FDA, and that review adds more time before a treatment reaches pharmacy shelves.
How Many People Participate in a Phase 3 Clinical Trial?
A Phase 3 clinical trial typically enrolls between 300 and 3,000 participants who have the condition the treatment is designed to address. That’s a large jump from the up to several hundred participants typical of Phase 2, and it’s intentional.
A bigger, more diverse group of participants makes it possible to detect side effects that only show up in a small percentage of people, and to see whether the treatment works consistently across different ages, backgrounds, and health profiles. This is also why Phase 3 trials are considered the strongest evidence for whether a treatment offers a real benefit, and why the informed consent process, overseen by an Institutional Review Board (IRB), is especially rigorous at this scale.
Disclosure: This page contains affiliate links. If you buy through them, we may earn a commission at no extra cost to you.
Why Do Clinical Trials Fail?
Clinical trials most often fail because a treatment doesn’t outperform a placebo or the standard treatment, or because side effects outweigh the benefit. The FDA’s own advancement figures reflect this: about 30% of drugs don’t make it past Phase 1, roughly two-thirds don’t make it past Phase 2, and a meaningful share still fail at Phase 3, the most expensive and time-consuming stage.
Trials can also fail for reasons that have nothing to do with whether a treatment works, including trouble enrolling enough qualified participants, poor study design, inconsistent dosing, or a control group that doesn’t isolate the effect being tested. This is one reason a single small or early-phase study is never strong enough, on its own, to support a broad health claim. Our guide to evaluating evidence quality walks through the factors that separate a promising early finding from a proven benefit.
What Happens After Phase 3? The FDA Approval Process
After Phase 3 trials succeed, the drug’s sponsor compiles all the preclinical and clinical data into a New Drug Application (NDA) and submits it to the FDA for review. The FDA has 60 days just to decide whether to accept the application for review.
Once accepted, the FDA’s review team, which includes medical officers, statisticians, and pharmacologists, examines the full dataset to decide whether the treatment is safe and effective for its intended use. Under the Prescription Drug User Fee Act, the FDA aims to act on standard applications within about 10 months, and priority applications within about 6 months, though the FDA’s own reporting shows actual review timelines vary. If approved, the drug enters Phase 4, where post-market surveillance continues to track safety and effectiveness in the general population, since far more people are exposed to the drug after approval than during any clinical trial.
How a Drug Goes From Lab to Pharmacy
The path from an early laboratory discovery to a product on a pharmacy shelf follows a defined sequence of regulatory steps. Here’s the overview:
- Discovery and preclinical research: Researchers identify a promising compound and test it in lab and animal models before it’s ever given to a person.
- Investigational New Drug (IND) application: The sponsor submits an IND to the FDA, including animal data and a clinical protocol, before human testing can begin.
- Phase 1 trials: A small group of volunteers helps establish basic safety and a tolerable dose range.
- Phase 2 trials: A larger patient group provides an early signal of effectiveness and more safety data.
- Phase 3 trials: A large, often randomized and placebo-controlled trial confirms whether the treatment offers a real benefit.
- New Drug Application (NDA): The sponsor submits the complete dataset to the FDA, requesting approval to market the drug.
- FDA review: FDA specialists evaluate the application’s safety, efficacy, and manufacturing data before deciding whether to approve it.
- Phase 4 post-market surveillance: After approval, ongoing monitoring tracks real-world safety and effectiveness across a much larger population.
Ingredient research behind health supplements doesn’t always follow every one of these steps, since dietary supplements aren’t approved by the FDA the way drugs are. That’s part of why it matters to check what stage of research actually backs a specific ingredient claim. Our guide on understanding clinical study design types explains how different study designs fit into this bigger picture.
Frequently Asked Questions
What’s the difference between a clinical trial and a clinical study?
“Clinical trial” usually refers to a study that tests an intervention, like a drug, device, or supplement ingredient, in human participants. “Clinical study” is a broader term that also includes observational research, where researchers watch outcomes without assigning a specific treatment. Our guide to reading a clinical study breaks down how to tell these designs apart.
Can a treatment skip a clinical trial phase?
Generally, no. Each phase builds on data from the one before it, and skipping a phase would mean moving forward without answering the safety or efficacy questions that phase is designed to catch. Some accelerated pathways exist for serious conditions with few treatment options, but they still require phased human testing.
Does a Phase 2 study prove a supplement ingredient works?
Not on its own. Phase 2 studies provide an early efficacy signal and more safety data, but they aren’t large or long enough to confirm a treatment benefit. That confirmation is what Phase 3 trials are designed to provide.
Who protects participants during a clinical trial?
An Institutional Review Board (IRB) reviews and approves the trial protocol before it begins, checking that the study is designed responsibly and that participants give informed consent after being told about the risks. The FDA’s IND review team also monitors safety data throughout the trial.
Why do some supplement products only cite early-phase or animal research?
Early-phase and preclinical research is often the only evidence available for a given ingredient, especially compared to FDA-regulated drugs that must complete all four phases. That doesn’t make the research meaningless, but it does mean the evidence is preliminary. Our piece on evidence vs. marketing claims explains how to read those citations critically.
Educational Disclaimer
This article is for educational purposes only and does not provide medical advice. It does not endorse or recommend any specific treatment, supplement, drug, or clinical trial. Always talk with a qualified healthcare provider before making decisions about your health. See our full Medical Disclaimer for more information.